Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Kaplan MD, MSc, FACP, FAASLD, AGAF

David E. Kaplan MD, MSc, FACP, FAASLD, AGAF

Associate Professor of Medicine and Director of Hepatology, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania; Director of Hepatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania

Dr. David E. Kaplan is an Associate Professor of Medicine and Director of Hepatology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Kaplan has served as Director of Hepatology at the Corporal Michael J. Crescenz Veterans Administration Medical Center where he has organized a regional hepatocellular carcinoma tumor board since 2014 with innovations recognized by the VA Diffusion of Excellence program. He has held multiple committee leadership roles in the AASLD including being the current Chairperson of the Liver Cancer SIG. He is an active clinician and mentor. Previous research focused on antigen-specific T-cell dysfunction in liver cancer and B-cell dysfunction related to cirrhosis, a key component of cirrhosis associated-immunodeficiency.  His research currently focuses on outcomes and clinical research in cirrhosis, portal hypertension, and hepatocellular carcinoma.


Dr. David E. Kaplan has received research grants paid to his institution from Gilead Inc. and Bayer Healthcare Inc., the NIH and VA. He has received compensation for advisory board participation with Exelixis Inc.